Literature DB >> 6230344

The pharmacokinetics and tissue penetration of norfloxacin.

Z N Adhami, R Wise, D Weston, B Crump.   

Abstract

The pharmacokinetics and cantharides-induced blister fluid levels of norfloxacin were studied after a single 400 mg oral dose. The mean maximum serum level was 1.45 mg/l and occurred 1.5 h after administration. The serum half-life of norfloxacin was found to be 3.5 h. After 24 h 27% of the administered dose was recovered in the urine as microbiologically active compound. High urine levels were found. Rapid blister fluid penetration occurred, the maximum level (occurring between 2-3 h) was about 1 mg/l. Thereafter the blister fluid level exceeded the serum level, both declining in parallel.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6230344     DOI: 10.1093/jac/13.1.87

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  33 in total

Review 1.  Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 2.  Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response.

Authors:  D E Nix; S D Goodwin; C A Peloquin; D L Rotella; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

3.  Tissue penetration and pharmacokinetics of lomefloxacin following multiple doses.

Authors:  J Kavi; J Stone; J M Andrews; J P Ashby; R Wise
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-02       Impact factor: 3.267

Review 4.  Antibiotic-containing polymers for localized, sustained drug delivery.

Authors:  Nicholas D Stebbins; Michelle A Ouimet; Kathryn E Uhrich
Journal:  Adv Drug Deliv Rev       Date:  2014-04-18       Impact factor: 15.470

5.  The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin.

Authors:  R Wise; D Lister; C A McNulty; D Griggs; J M Andrews
Journal:  Infection       Date:  1986       Impact factor: 3.553

Review 6.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

7.  In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.

Authors:  K G Naber; F Sörgel; F Gutzler; B Bartosik-Wich
Journal:  Infection       Date:  1985 Sep-Oct       Impact factor: 3.553

8.  Pharmacokinetics and tissue penetration of orally administered lomefloxacin.

Authors:  J W Stone; J M Andrews; J P Ashby; D Griggs; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

9.  Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers.

Authors:  J A Cook; M H Silverman; D J Schelling; D E Nix; J J Schentag; R R Brown; R M Stroshane
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 10.  Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; R N Brogden; D M Richards
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.